EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study

Heejoon Jang, Yeonjin Kim, Yoo Kyoung Lim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Gi-Ae Kim, Woojoo Lee, Stefano Romeo, Won Kim, Innovative Target Exploration of NAFLD (ITEN) consortium

Clinical and Molecular Hepatology · 01.04.2026 · 32 (2) · 737-750

DOI: 10.3350/cmh.2025.1006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2026. Verfasst von Heejoon Jang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Type 2, Fatty Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Education, Korean Association for the Study of the Liver.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Patients with concurrent type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) face elevated cardiovascular risks. However, optimal oral antidiabetic drug (OAD) selection for this population remains unclear.

Methods

Using the Korean National Health Information Database, we conducted a target trial emulation comparing cardiovascular outcomes among patients with T2DM and MASLD (defined by fatty liver index ≥30) who initiated sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, or sulfonylureas with metformin. The primary outcome was major adverse cardiovascular events (MACE), including cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke.

Results

Among 71,071 patients (331,726 person-years), SGLT2 inhibitor users experienced a significantly lower MACE risk compared to sulfonylurea users (adjusted subdistribution hazard ratio [aSHR], 0.44; 95% confidence interval [CI], 0.31–0.62). SGLT2 inhibitors also demonstrated a lower MACE risk compared to thiazolidinediones (aSHR, 0.61; 95% CI, 0.39–0.96) and DPP-4 inhibitors (aSHR, 0.59; 95% CI, 0.42–0.83). Cardiovascular mortality risk was notably reduced with SGLT2 inhibitors compared to sulfonylureas (aSHR, 0.13; 95% CI, 0.03–0.50), thiazolidinediones (aSHR, 0.19; 95% CI, 0.04–0.86), and DPP-4 inhibitors (aSHR, 0.22; 95% CI, 0.06–0.84). Mediation analysis revealed that MASLD regression accounted for 8.7% of the total cardiovascular benefit when comparing SGLT2 inhibitors to sulfonylureas.

Conclusions

In patients with concurrent T2DM and MASLD, SGLT2 inhibitors demonstrated better cardiovascular outcomes compared to other OADs. These findings suggest that SGLT2 inhibitors may be the preferred OAD choice for cardiovascular risk reduction in this high-risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsDiabetes Mellitus, Type 2Fatty LiverHumansMaleFemaleMiddle AgedSodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsAgedSulfonylurea CompoundsCardiovascular DiseasesThiazolidinedionesMetforminDatabases, FactualAdministration, OralTreatment OutcomeRepublic of KoreaProportional Hazards Models

Stichwörter der Autor:innen

Cardiovascular diseasesCerebrovascular disordersDiabetes mellitusHypoglycemic agentsNon-alcoholic fatty liver disease

Substanzen

Hypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsSulfonylurea CompoundsThiazolidinedionesMetformin

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea.
  • Department of Public Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, Korea.
  • Department of Internal Medicine, College of Medicine, Kyung Hee University Hospital, Kyung Hee University, Seoul, Korea.
  • Center for Reproduction, Metabolism and Molecular Medicine (CeRM), Department of Medicine (H7), Karolinska Institute, Huddinge, Stockholm, Sweden.

Förderung

  • National Research Foundation of Korea
  • Ministry of Education
  • Korean Association for the Study of the Liver
  • Seoul National University

Zitieren

APA

Jang, H., Kim, Y., Lim, Y. K., Lee, D. H., Joo, S. K., Koo, B. K., Kim, G. A., Lee, W., Romeo, S., Kim, W., & Innovative Target Exploration of NAFLD (ITEN) consortium (2026). Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study. Clinical and Molecular Hepatology, 32(2), 737-750. https://doi.org/10.3350/cmh.2025.1006

Vancouver

Jang H, Kim Y, Lim YK, Lee DH, Joo SK, Koo BK, et al. Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study. Clinical and Molecular Hepatology. 2026;32(2):737-750. doi:10.3350/cmh.2025.1006

BibTeX
@article{Jang2026,
  author = {Jang, Heejoon and Kim, Yeonjin and Lim, Yoo Kyoung and Lee, Dong Hyeon and Joo, Sae Kyung and Koo, Bo Kyung and Kim, Gi-Ae and Lee, Woojoo and Romeo, Stefano and Kim, Won and Innovative Target Exploration of NAFLD (ITEN) consortium, Innovative Target Exploration of NAFLD (ITEN) consortium},
  title = {Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {2},
  pages = {737--750},
  doi = {10.3350/cmh.2025.1006}
}
Kostenlos starten →